1. AAV8-vectored suprachoroidal gene transfer was used to produce widespread ocular transgene expression.
2. Researchers from the Wilmer Eye Institute at Johns Hopkins University School of Medicine and REGENXBIO Inc. collaborated on this study.
3. The authorship note states that KD and JS contributed equally to the work.
The article is generally reliable and trustworthy, as it is published in a reputable journal (JCI) and is written by researchers from two well-known institutions (Johns Hopkins University School of Medicine and REGENXBIO Inc.). The authors provide detailed information about their methods, results, and conclusions, which allows readers to evaluate the trustworthiness of the article for themselves. Additionally, the authorship note states that KD and JS contributed equally to the work, which suggests that there are no potential biases due to unequal contributions from different authors.
However, there are some potential issues with the article's trustworthiness and reliability. For example, while the authors provide detailed information about their methods and results, they do not discuss any possible risks associated with AAV8-vectored suprachoroidal gene transfer or explore any counterarguments or alternative perspectives on their findings. Additionally, while they cite other relevant studies throughout the article, they do not present both sides of an argument equally; instead, they focus primarily on supporting their own claims without providing much evidence for opposing views or perspectives. Finally, there is a possibility that some of the content in the article may be promotional in nature; however, this cannot be confirmed without further research into REGENXBIO Inc., which was not conducted for this critical report.